Is XTL BIOPHARMACEUTICALS LTD (XTLB) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 2.0% / 30% | 16.6% / 30% | 2.2% / 30% | 7.54% / 5% | ✗ NOT HALAL |
| DJIM | 2.0% / 33% | 16.6% / 33% | 2.2% / 33% | 7.54% / 5% | ✗ NOT HALAL |
| MSCI | 1.6% / 33% | 13.4% / 33% | 1.8% / 33% | 7.54% / 5% | ✗ NOT HALAL |
| S&P | 2.0% / 33% | 16.6% / 33% | 2.2% / 33% | 7.54% / 5% | ✗ NOT HALAL |
| FTSE | 1.6% / 33% | 13.4% / 33% | 1.8% / 50% | 7.54% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | -232.9% | |
| Operating Margin | -853.6% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -577.1% | |
| Return on Assets (ROA) | -240.6% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$2M |
| Free Cash Flow | -$2M |
| Total Debt | $138,000 |
| Current Ratio | 0.7 |
| Total Assets | $9M |
Price & Trading
| Last Close | $2.63 |
| 50-Day MA | $3.24 |
| 200-Day MA | $4.31 |
| Avg Volume | 736K |
| Beta | 0.7 |
|
52-Week Range
$2.12
| |
About XTL BIOPHARMACEUTICALS LTD (XTLB)
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. Its lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. The company has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is XTL BIOPHARMACEUTICALS LTD (XTLB) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), XTL BIOPHARMACEUTICALS LTD is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is XTL BIOPHARMACEUTICALS LTD's debt ratio?
XTL BIOPHARMACEUTICALS LTD's debt ratio is 2.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 1.6%.
What are XTL BIOPHARMACEUTICALS LTD's key financial metrics?
XTL BIOPHARMACEUTICALS LTD has a market capitalization of $6M, and revenue of $451,000. Return on equity stands at -577.1%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.